Cardiomyopathy is a leading cause of heart failure in children, and there are currently no effective treatments. Could emerging therapies that successfully target the root cause of the condition in adults also work well in children? That was the question Dr....
In the realm of cardiac health, an exciting new study has cast light on the intricate details of our hearts, revealing significant differences between the left and right ventricles' fibroblasts. This research, conducted by a team of dedicated scientists from the...
For children diagnosed with complex heart conditions like hypertrophic cardiomyopathy (HCM), the diagnosis can be frightening for families and challenging for healthcare providers since the trajectory of the condition is often uncertain. As a leading cause of sudden...
An innovative cardiovascular start-up, HDAX Therapeutics, is the latest company to win $250,000 in funding following another year of the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) program. The ECHO program...
Several members of the Ted Rogers Centre for Heart Research (TRCHR) participated in Vascular 2023, a five-day conference held in Montreal from October 25-29. The conference is a hallmark event organized by several Canadian specialist and research organizations,...
Researchers at the Ted Rogers Centre for Heart Research have developed an innovative approach to better understanding the complex signaling mechanisms underlying heart failure. A recent publication in the Proceedings of the National Academy of Sciences (PNAS) offers...
The Ted Rogers Centre and its partners are committed to helping commercialize new cardiovascular innovations and technologies so they may reach the market sooner.
The ECHO program is a key part of that mission – and is open to any Canadian-based clinician, scientist, entrepreneur and/or student. Applications for the 2020-21 year closed on August 28th.
To reach teams across Canada, ECHO is now entirely virtual, beginning in 2020. We are pleased to announce a call for applications for the 2020-2021 ECHO program.
Founded in 2018, ECHO is a 12-month online training program led by veteran entrepreneurs and high-calibre consultants across a variety of sectors. Comprised of a unique combination of five complementary modules, ECHO provides innovators of cardiovascular technologies with entrepreneurship training, mentorship, and networking opportunities, and the chance to pitch for start-up funding from a $250,000 pool.
Please visit our ECHO website for more details.
ECHO is organized and funded by the Translational Biology and Engineering Program (TBEP) – the University of Toronto component of the Ted Rogers Centre for Heart Research – in partnership with the Health Innovation Hub (H2i), a University of Toronto campus-linked accelerator.
